Inventor · disambiguated record
Chad A. Cowan
Also filed as: COWAN CHAD · COWAN CHAD A · COWAN CHAD ALBERT
18 granted patents·32 pending applications·150 citations·filing 2009–2025
93Inventor score
Files withHARVARD COLLEGE24CRISPR THERAPEUTICS AG12VERTEX PHARMA8GEN HOSPITAL CORP2HOFFMANN LA ROCHE2
Top patents by PatentIndex Score
50 records- 0197US10968426B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2016·Granted Apr 6, 2021·27 cites·23 claims
- 0296US12031155B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2022·Granted Jul 9, 2024·2 cites·32 claims
- 0396US12031154B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2022·Granted Jul 9, 2024·2 cites·32 claims
- 0496US9822370B2Method of making a deletion in a target sequence in isolated primary cells using Cas9 and two guide RNAsHARVARD COLLEGE·Filed 2014·Granted Nov 21, 2017·98 cites·12 claims
- 0595US12110500B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2022·Granted Oct 8, 2024·1 cites·33 claims
- 0695US11492591B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2021·Granted Nov 8, 2022·2 cites·19 claims
- 0791US12497590B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2024·Granted Dec 16, 2025·0 cites·30 claims
- 0889US10208319B2Therapeutic uses of genome editing with CRISPR/Cas systemsHARVARD COLLEGE·Filed 2014·Granted Feb 19, 2019·12 cites·11 claims
- 0985US12421493B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2022·Granted Sep 23, 2025·0 cites·32 claims
- 1084US11866727B2Materials and methods for treatment of glycogen storage disease type 1ACRISPR THERAPEUTICS AG·Filed 2016·Granted Jan 9, 2024·4 cites·6 claims
- 1182US2025064980A1Materials and Methods for Treatment of Duchenne Muscular DystrophyVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1279US2025333473A1Cells lacking b2m surface expression and methods for allogeneic administration of such cellsHARVARD COLLEGE·Filed 2024·Application pending·0 cites
- 1378US12053531B2Materials and methods for treatment of Duchenne Muscular DystrophyVERTEX PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·5 claims
- 1478US11369692B2Materials and methods for treatment of Duchenne Muscular DystrophyVERTEX PHARMA·Filed 2016·Granted Jun 28, 2022·1 cites·3 claims
- 1578US11083799B2Materials and methods for treatment of hereditary haemochromatosisCRISPR THERAPEUTICS AG·Filed 2017·Granted Aug 10, 2021·1 cites·16 claims
- 1678US2024226339A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 1777US11618881B2Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2021·Granted Apr 4, 2023·0 cites·29 claims
- 1874US2022333119A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 1973US12186406B2Materials and methods for treatment of hereditary haemochromatosisCRISPR THERAPEUTICS AG·Filed 2021·Granted Jan 7, 2025·0 cites·20 claims
- 2073US2024175014A1Materials and methods for treatment of alpha-1 antitrypsin deficiencyCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2172US2024229078A1Materials and methods for treatment of glycogen storage disease type 1aCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 2272US2025242061A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2025·Application pending·0 cites
- 2371US2025171800A1Materials and Methods for Treatment of HemoglobinopathiesVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 2470US2021277423A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 2570US2021285015A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 2670US2022162555A1Modified t cells and methods of making and using the sameHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 2770US2022211874A1Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2022·Application pending·0 cites
- 2869US2022162554A1Modified t cells and methods of making and using the sameHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 2966US2019201553A1Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 3066US2025235561A1Materials and methods for treatment of hereditary haemochromatosisCRISPR THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 3166US2021274726A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 3265US2025205357A1Targeted delivery of armmsHARVARD COLLEGE·Filed 2023·Application pending·0 cites
- 3363US2018291383A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2017·Application pending·0 cites
- 3461US2020330609A1Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 3560US2015176013A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2014·Application pending·0 cites
- 3660US2020048659A1THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMSHARVARD COLLEGE·Filed 2019·Application pending·0 cites
- 3755US12180263B2Cells lacking B2M surface expression and methods for allogeneic administration of such cellsHARVARD COLLEGE·Filed 2015·Granted Dec 31, 2024·0 cites·8 claims
- 3855US2021171903A1Universal donor stem cells and related methodsHARVARD COLLEGE·Filed 2020·Application pending·0 cites
- 3953US2011195056A1Compositions comprising hepatocyte-like cells and uses thereofGEN HOSPITAL CORP·Filed 2009·Application pending·0 cites
- 4052US11851653B2Materials and methods for treatment of alpha-1 antitrypsin deficiencyCRISPR THERAPEUTICS AG·Filed 2016·Granted Dec 26, 2023·0 cites·5 claims
- 4151US2021247385A1Methods for assessing transendothelial barrier integrityHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4250US2021222122A1Synergistic transcription factors to induce high resistance transendothelial barrierHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4350US2022267732A1Dux4 expressing cells and uses thereofSANA BIOTECHNOLOGY INC·Filed 2020·Application pending·0 cites
- 4448US12043843B2Materials and methods for treatment of hemoglobinopathiesCRISPR THERAPEUTICS AG·Filed 2016·Granted Jul 23, 2024·0 cites·12 claims
- 4548US2012219530A1Compositions and methods of generating reprogrammed adipocyte cells and methods of use thereforeLUM DAVID H·Filed 2011·Application pending·0 cites
- 4648US2016348073A1Modified t cells and methods of making and using the sameHARVARD COLLEGE·Filed 2016·Application pending·0 cites
- 4746US2021180091A1Materials and methods for treatment of hemoglobinopathiesVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 4846US2015004144A1Differentiation into brown adipocytesGEN HOSPITAL CORP·Filed 2012·Application pending·0 cites
- 4943US2021260219A1Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degenerationCRISPR THERAPEUTICS AG·Filed 2016·Application pending·0 cites
- 5038US2019038771A1Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndromeCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chad A. Cowan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →